Endothelial cells in the pathogenesis of pulmonary arterial hypertension.
Colin E EvansNicholas D CoberZhiyu DaiDuncan J StewartYou-Yang ZhaoPublished in: The European respiratory journal (2021)
Pulmonary arterial hypertension (PAH) is a devastating disease that involves pulmonary vasoconstriction, small vessel obliteration, large vessel thickening and obstruction, and development of plexiform lesions. PAH vasculopathy leads to progressive increases in pulmonary vascular resistance, right heart failure and, ultimately, premature death. Besides other cell types that are known to be involved in PAH pathogenesis (e.g. smooth muscle cells, fibroblasts and leukocytes), recent studies have demonstrated that endothelial cells (ECs) have a crucial role in the initiation and progression of PAH. The EC-specific role in PAH is multi-faceted and affects numerous pathophysiological processes, including vasoconstriction, inflammation, coagulation, metabolism and oxidative/nitrative stress, as well as cell viability, growth and differentiation. In this review, we describe how EC dysfunction and cell signalling regulate the pathogenesis of PAH. We also highlight areas of research that warrant attention in future studies, and discuss potential molecular signalling pathways in ECs that could be targeted therapeutically in the prevention and treatment of PAH.
Keyphrases
- pulmonary arterial hypertension
- pulmonary hypertension
- polycyclic aromatic hydrocarbons
- endothelial cells
- pulmonary artery
- heart failure
- single cell
- oxidative stress
- cell therapy
- multiple sclerosis
- working memory
- mesenchymal stem cells
- risk assessment
- current status
- single molecule
- peripheral blood
- drug delivery
- vascular endothelial growth factor
- climate change
- human health
- combination therapy